(Q42667417)

4 November 2017

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension (English)

1 reference

4 November 2017

1 reference

Mardi Gomberg-Maitland

1

1 reference

4 November 2017

Victor F Tapson

2

1 reference

4 November 2017

Raymond L Benza

3

1 reference

4 November 2017

Vallerie V McLaughlin

4

1 reference

4 November 2017

Abigail Krichman

5

1 reference

4 November 2017

Allison C Widlitz

6

1 reference

4 November 2017

Robyn J Barst

7

1 reference

4 November 2017

language of work or name

English

0 references

publication date

8 September 2005

1 reference

American Journal of Respiratory and Critical Care Medicine

4 November 2017

1 reference

4 November 2017

172

1 reference

4 November 2017

12

1 reference

4 November 2017

1586-1589

1 reference

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

4 November 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

Treatment of pulmonary hypertension secondary to connective tissue diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200505-766OC

10.1164/RCCM.200505-766OC

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference